IRIS
SOTO PARRA, HECTOR
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.309
AS - Asia 1.791
EU - Europa 1.493
SA - Sud America 407
AF - Africa 175
OC - Oceania 6
Totale 7.181
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.238
SG - Singapore 1.127
RU - Federazione Russa 581
BR - Brasile 351
IE - Irlanda 321
CN - Cina 265
VN - Vietnam 144
IT - Italia 137
FR - Francia 109
BE - Belgio 92
NG - Nigeria 77
IN - India 53
CI - Costa d'Avorio 50
DE - Germania 43
GB - Regno Unito 41
CA - Canada 39
KR - Corea 37
UA - Ucraina 36
HK - Hong Kong 35
AT - Austria 20
MX - Messico 20
BD - Bangladesh 17
NL - Olanda 17
PL - Polonia 17
AR - Argentina 16
TR - Turchia 15
IQ - Iraq 14
IR - Iran 14
ID - Indonesia 13
FI - Finlandia 12
SE - Svezia 10
VE - Venezuela 10
ES - Italia 9
UZ - Uzbekistan 9
CH - Svizzera 8
EC - Ecuador 8
EG - Egitto 8
BG - Bulgaria 7
JP - Giappone 7
KE - Kenya 7
LT - Lituania 7
MA - Marocco 7
ZA - Sudafrica 7
BJ - Benin 6
CO - Colombia 6
PE - Perù 6
PH - Filippine 5
SN - Senegal 5
CL - Cile 4
LB - Libano 4
PK - Pakistan 4
RS - Serbia 4
AL - Albania 3
AU - Australia 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
IL - Israele 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
UY - Uruguay 3
AZ - Azerbaigian 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
HR - Croazia 2
HU - Ungheria 2
JO - Giordania 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MY - Malesia 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
TH - Thailandia 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BT - Bhutan 1
BY - Bielorussia 1
DZ - Algeria 1
GH - Ghana 1
GL - Groenlandia 1
GR - Grecia 1
KG - Kirghizistan 1
KW - Kuwait 1
LY - Libia 1
MD - Moldavia 1
NP - Nepal 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PY - Paraguay 1
RO - Romania 1
SV - El Salvador 1
Totale 7.181
Salva come PNG Salva come JPEG
Città #
Santa Clara 684
Singapore 607
Dallas 435
Chandler 343
Dublin 316
Chicago 213
Moscow 184
Ashburn 147
San Jose 143
Boardman 121
Beijing 102
Brussels 92
Cambridge 88
Lawrence 88
Andover 83
Lauterbourg 80
Ho Chi Minh City 60
Des Moines 59
Los Angeles 53
Abidjan 50
Abuja 43
Catania 39
São Paulo 39
The Dalles 37
Hong Kong 35
Seoul 35
Hefei 34
Columbus 28
Houston 28
Lagos 27
Wilmington 27
Buffalo 24
Bremen 23
Council Bluffs 23
Hanoi 23
Jacksonville 22
Orem 19
Saint Petersburg 17
Rio de Janeiro 14
Civitanova Marche 12
New York 12
Toronto 12
Warsaw 12
Kochi 11
Leawood 11
Falls Church 10
Lappeenranta 10
Montreal 9
Ottawa 9
Curitiba 8
Amsterdam 7
Baghdad 7
Chennai 7
Jakarta 7
Mexico City 7
Milan 7
Mumbai 7
Port Harcourt 7
Ardabil 6
Brooklyn 6
Campinas 6
Cotonou 6
Da Nang 6
Guarulhos 6
Nuremberg 6
Pune 6
Redondo Beach 6
Rome 6
San Mateo 6
Seattle 6
Stockholm 6
Atlanta 5
Boston 5
Cairo 5
Dakar 5
Istanbul 5
London 5
Nanjing 5
Phoenix 5
Poplar 5
Porto Alegre 5
Shenyang 5
Sofia 5
Vienna 5
Aci Catena 4
Bauru 4
Belgrade 4
Belo Horizonte 4
Brasília 4
Bussero 4
Denver 4
Edinburgh 4
Frankfurt am Main 4
Hortolândia 4
Lima 4
Nairobi 4
Quezon City 4
Salvador 4
San Francisco 4
Shanghai 4
Totale 4.864
Salva come PNG Salva come JPEG
Nome #
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC 141
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 132
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles 130
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions 123
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: A retrospective Italian study 117
Benign form of Myasthenia Gravis after Nivolumab treatment 116
Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: Preliminary experience 116
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 112
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma 112
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer 110
Benign form of myasthenia gravis after nivolumab treatment 109
Direct Left Ventricular Metastasis Reduction: 3D-Echo Monitoring For Management of Clinical Case 109
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 109
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 102
Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-smal-cell lung cancer 101
Early Gastrointestinal Progression to Immunotherapy in Lung Cancer: A Report of Two Cases 101
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients 99
Nutritional support in patients with cancer of the esophagus: Impact on nutritional status, patient compliance to therapy, and survival 99
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study 99
Ceritinib in the treatment of an adult patient with advanced neuroblastoma positive to the somatic activating mutation of ALK F1174L 99
Combined regimen of cisplatin, doxorubicin, and α-2b interferon in the treatment of advanced malignant pleural mesothelioma: A phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP) 98
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: attempts to improve long-term outcome 98
Bladder Cancer 97
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer 95
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S 95
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 92
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer 90
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial 90
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida) 87
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 87
Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: Initial experience 84
First-line lorlatinib or crizotinib in advanced alk-positive lung cancer 83
Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma 80
Ifosfamide and vinorelbine: An active regimen for patients with relapsed or refractory Hodgkin's disease 79
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma 79
Valutazione economica in base allo studio NAVoTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato 78
Pre-operative hyperfractionated radiotherapy and 5-Fluorouracil continuous infusion in elderly patients with locally advanced primary rectal cancer (LA-PRC): feasibility, pathologic complete response, sphincter preservation and local control 77
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 76
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 75
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 74
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) 74
ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients 74
Treatment perspectives in advanced non-small cell lung cancer 73
Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study 73
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer 72
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC 71
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 71
Phase ii prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy 71
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: Clinical and molecular results from a prospective study 71
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC 71
Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study 71
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report 71
Malignant pleural mesothelioma: The gemcitabine-vinorelbine combination in pemetrexed-pretreated patients 70
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study 70
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 69
Uncommon manifestations of common malignancies - Case 1. Soft-tissue metastases from malignant pleural mesothelioma 69
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: A new category of patients for clinical studies? 69
Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour 69
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 69
Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer 69
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) 67
Three-week versus four-week schedule of cisplatin and gemcitabine: Results of a randomized phase II study 67
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 67
Histology-based combination induction chemotherapy for elderly patients with clinical stage III non-small cell lung cancer 66
Epicure: A European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy 66
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 65
Extensive experience of disease control with gefitinib and the role of prognostic markers 65
Lessons from the ‘iressa’ expanded access programme: Gefitinib in special non-small-cell lung cancer patient populations 65
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer 64
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: A retrospective analysis 63
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study 63
Palbociclib in hormone-receptor-positive advanced breast cancer 62
Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES study 62
Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria 61
Lack of response to imatinib mesylate as second-line therapy in a patient with c-kit positive metastatic soft tissue leiomyosarcoma 61
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 60
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 59
Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: A whatsapp messenger-based report from the Italian college of chief medical oncologists 59
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 59
The evolution of surgery in non-small cell lung cancer 58
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 58
Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus 58
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial 57
The impact of the SARS-CoV-2 outbreak on the psychological flexibility and behaviour of cancelling medical appointments of italian patients with pre-existing medical condition: The “impact-COVID-19 for patients” multi-centre observational study 57
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer 57
Italian cohort of the nivolumab EAP in squamous NSCLC: Efficacy and safety in patients with CNS metastases 56
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas 56
Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer 56
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 54
Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study 53
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 53
Soft tissue and bone sarcomas 51
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial 46
Totale 7.338
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.804
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.804
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202144 0 0 0 0 0 0 0 0 0 0 44 0
2021/2022458 9 54 0 2 58 51 85 23 19 1 38 118
2022/20231.096 94 16 25 133 85 207 3 171 263 5 52 42
2023/2024363 23 131 8 9 9 56 11 20 0 2 55 39
2024/20252.155 42 325 93 76 520 318 44 88 154 280 135 80
2025/20262.937 188 98 492 178 620 585 399 109 139 129 0 0
Totale 7.338